Lead Sponsor

Pfizer

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•Histologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous component
•Patients must be candidates for platinum based chemotherapy and previously untreated
•Patients must have completed a surgical debulking procedure, or be candidates for neoadjuvant chemotherapy
•Availability of an archival formalin fixed, paraffin embedded (FFPE) tumor tissue block or a minimum of 15 slides
•ECOG PS 0-1
•Adequate hematological, renal, and liver function

•Non epithelial tumors or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors
•Prior systemic anti-cancer treatment for EOC, FTC, or PPC including prior immunotherapy with IL 2, IFN α, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways
•Patients for whom, in the opinion of the Investigator, there is clinical benefit to administer bevacizumab as a first-line treatment and for whom bevacizumab is approved and available in this setting.
•Cancer for which intraperitoneal cytotoxic chemotherapy is planned
•Active autoimmune disease (some exceptions include diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroidism not requiring immunosuppressive treatment)

Related studies

NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more

NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more

NCT07144826 · Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, and more

NCT05364879 · Prehabilitation, Exercise, and more

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)